 Acceleron Pharma Inc NASDAQ: XLRN has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension PAH. The data were presented at the American Thoracic Society 2021 International Conference. 